Dermal penetration enhancers and drug delivery systems involving same
US6818226B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2001 |
| Grant date | Nov 16, 2004 |
| Priority date | — |
| Expiry date | Apr 7, 2022 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen.A non-occlusive, percutaneous or transdermal drug delivery system which comprises:(i) an effective amount of at least one physiologically active agent or prodrug thereof;(ii) at least one non-volatile dermal penetration enhancer; and(iii) at least one volatile liquid;characterised in thatthe dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane;and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.